Cargando…

Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study

INTRODUCTION: Ultra-rapid lispro (URLi) is a new prandial insulin lispro formulation. In the PRONTO-T2D study, URLi, in a basal-bolus regimen with glargine or degludec, was non-inferior to lispro (Humalog(®)) for HbA1c reduction and superior for postprandial glucose (PPG) control. We evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qianyi, Chigutsa, Farai, Chang, Annette M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309112/ https://www.ncbi.nlm.nih.gov/pubmed/35781789 http://dx.doi.org/10.1007/s13300-022-01290-4

Ejemplares similares

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
por: Blevins, Thomas, et al.
Publicado: (2020)

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021)

Efficacy and Safety of Ultra-Rapid Lispro Versus Lispro in Patients with Type 1 and 2 Diabetes: Indian Subpopulation Analyses of the PRONTO-T1D and PRONTO-T2D Trials
por: Bhattacharyya, Arpandev, et al.
Publicado: (2022)

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
por: Wadwa, R. Paul, et al.
Publicado: (2022)

Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
por: Bailey, Timothy S., et al.
Publicado: (2023)

What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
por: Heise, Tim, et al.
Publicado: (2022)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis
por: Jinnouchi, Hideaki, et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension
por: Bue-Valleskey, Juliana, et al.
Publicado: (2021)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog(®) in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis
por: Miura, Junnosuke, et al.
Publicado: (2020)

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
por: Klaff, Leslie, et al.
Publicado: (2020)

Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy
por: Malecki, Maciej T., et al.
Publicado: (2020)

Long-term Efficacy and Safety of Ultra Rapid Lispro in Japanese Patients With Type 1 Diabetes: Subpopulation Analysis of the 52-Week PRONTO-T1D Study
por: Miura, Junnosuke, et al.
Publicado: (2021)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials
por: Liao, Birong, et al.
Publicado: (2021)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
por: Leohr, Jennifer, et al.
Publicado: (2020)

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
por: Ishii, Takahiro, et al.
Publicado: (2021)

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
por: Shiramoto, Masanari, et al.
Publicado: (2020)

Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2023)

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
por: Thrasher, James, et al.
Publicado: (2018)

No perdones demasiado pronto
por: Linn, Dennis
Publicado: (2004)

De pronto abril
por: Ríos, Soleida, 1950-

A bote pronto /
por: Cela, Camilo José, 1916-2002
Publicado: (1994)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
por: Leohr, Jennifer, et al.
Publicado: (2021)

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
por: Heise, Tim, et al.
Publicado: (2020)

Qué pronto se hace tarde /
por: Leñero, Vicente
Publicado: (1997)

Prima che tu dica "Pronto"
por: Calvino, Italo

Fisica acceleratore LHC e' pronto
Publicado: (2008)

Fisica acceleratore LHC e' pronto
Publicado: (2008)

Il superacceleratore pronto a ripartire
Publicado: (2009)

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study
por: Kazda, Christof, et al.
Publicado: (2021)

PRoNTo: Pattern Recognition for Neuroimaging Toolbox
por: Schrouff, J., et al.
Publicado: (2013)

Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
por: Yamashiro, Keiko, et al.
Publicado: (2010)

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
por: Home, Philip, et al.
Publicado: (2018)

Tutto pronto per creare un buco nero
Publicado: (2008)

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
por: Blevins, T., et al.
Publicado: (2016)

Inattentional Blindness During Driving in Younger and Older Adults
por: Saryazdi, Raheleh, et al.
Publicado: (2019)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Bing-li, et al.
Publicado: (2018)

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine
por: Buse, John B., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rkfiqaa6fbvdc4mqvtbgt97sjd